 |
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
|
PRISMEDICAL News
FOR IMMEDIATE RELEASE
PRISMEDICAL CORPORATION ANNOUNCES FDA CLEARANCE FOR STERILE PURIFIED WATER DEVICE
San Francisco, California May 7, 2002 - PRISMEDICAL CORPORATION today announced it had received clearance from the U.S. Food and Drug Administration for MainStream®, an advanced portable water purification device capable of producing sterile purified water on-demand at the point of use. This "real time" technology expands the reach and reduces the cost of fluid therapies by empowering healthcare providers and patients with the capability to deliver fluid therapies. This "real time" technology also enables significant improvements in Homeland Security by improving civilian and military medical preparedness and rapid response to life threatening events in prehospital settings.
"MainStream is a radical departure from the conventional methods of production and delivery of sterile water," said Mark Sizelove, President & CEO of PRISMEDICAL . "Sterile water is the common denominator in fluid therapy and is used as the diluent and carrier of a broad spectrum of beneficial therapeutic agents. The portability and convenience of MainStream, coupled with the ability to operate without power, will advance medical mobility for sterile water and eventually for all fluid therapies. We believe our patented technology platforms will transform medical practice with products that change how, when and where fluid therapies are delivered."
PRISMEDICAL CORPORATION is a privately held company, located in Napa, California, specializing in the development of disposable, hand-held medical systems that deliver fluid therapies on-demand at the point-of-use. The five-year product launch centers on sales of water devices followed by combination devices which integrate the company's pharmaceutical grade water and therapeutic delivery technologies.
Proof of concept studies by PRISMEDICAL support the future development of a product pipeline delivering fluid therapies and creating a series of "prevention and treatment" products for oral, intravenous, intramuscular and intraperitoneal administration.
TOP
PRISMEDICAL CORPORATION ANNOUNCES FDA CLEARANCE FOR STERILE PURIFIED WATER DEVICE
San Francisco, California May 7, 2002 - PRISMEDICAL CORPORATION today announced it had received clearance from the U.S. Food and Drug Administration for MainStream®, an advanced portable water purification device capable of producing sterile purified water on-demand at the point of use. This "real time" technology expands the reach and reduces the cost of fluid therapies by empowering healthcare providers and patients with the capability to deliver fluid therapies. This "real time" technology also enables significant improvements in Homeland Security by improving civilian and military medical preparedness and rapid response to life threatening events in prehospital settings.
"MainStream is a radical departure from the conventional methods of production and delivery of sterile water," said Mark Sizelove, President & CEO of PRISMEDICAL . "Sterile water is the common denominator in fluid therapy and is used as the diluent and carrier of a broad spectrum of beneficial therapeutic agents. The portability and convenience of MainStream, coupled with the ability to operate without power, will advance medical mobility for sterile water and eventually for all fluid therapies. We believe our patented technology platforms will transform medical practice with products that change how, when and where fluid therapies are delivered."
PRISMEDICAL CORPORATION is a privately held company, located in Napa, California, specializing in the development of disposable, hand-held medical systems that deliver fluid therapies on-demand at the point-of-use. The five-year product launch centers on sales of water devices followed by combination devices which integrate the company's pharmaceutical grade water and therapeutic delivery technologies.
Proof of concept studies by PRISMEDICAL support the future development of a product pipeline delivering fluid therapies and creating a series of "prevention and treatment" products for oral, intravenous, intramuscular and intraperitoneal administration.
TOP